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GUEST EDITORIAL
Flavone acetic acid - an interesting novel therapeutic agent or just another
disappointment?
M.C. Bibby
Clinical Oncology Unit, University ofBradford, Bradford BD7 IDP, UK.
There is a real need to develop drugs which are active in
common solid cancers but which are not limited in their
usage by life threatening host toxicity. A tall order perhaps
but nevertheless a worthwhile goal for the experimentalist.
The search therefore goes on to identify new targets which
will provide that elusive tumour cell specificity. One way of
achieving selectivity might be to progress compounds on the
basis of differential anti-cancer activity in pre-clinical screens.
One agent which has greater activity against solid tumours in
mice than against murine leukaemias, i.e. solid tumour
specificity, is flavone acetic acid, NSC 347512 (FAA). This
compound also has the advantage of being a novel chemical
structure compared with existing anti-cancer drugs and
belonging to a class of chemical with a wide range of
biological properties (Cody et al., 1988). Early in the
developmental programme of the National Cancer Institute
(NCI) more than 200 flavonoids were screened against
murine tumour systems including adenocarcinoma 755, sar-
coma 180 and leukaemia L1210. None of these was shown to
be active but quercetin was retested in 1971 and modest
activity was seen against P388 leukaemia implanted in the
peritoneal cavity (Plowman et al., 1986). As a result of these
early observations the NCI screened a series of flavones from
Lyonnaise Industrielle Pharmaceutique (Lipha) with a view
to utilising the new screen which emerged in 1975. They used
P388 as a pre-screen followed by a new panel of solid
tumours for secondary evaluation (Venditti et al., 1984).
Flavone acetic acid ester, NSC 293015 (LM985) (Figure 1)
emerged as a lead compound from this screen as it showed
good activity against P388 and also against the generally
refractory subcutaneously implanted colon adenocarcinoma
38 (Plowman et al., 1986).
As a result of the pre-clinical solid tumour activity, flavone
acetic acid ester was selected for clinical trial. LM985 did not
cause myelosuppression or major organ toxicity so there was
the suggestion of a novel mechanism of action. LM985 went
into phase I clinical trial in the UK in 1985 (Kerr et al.,
1985, 1987) and the authors suggested that the hydrolysis
product FAA (LM975) may be the active principal and that
substantially higher doses of FAA might be given without
dose limiting hypotension. Pharmacokinetic studies of
LM985 in mice demonstrated rapid hydrolysis to FAA so it
was clear that the acid was responsible for the dramatic
anti-tumour effects seen in subcutaneous mouse tumours
(Double et al., 1986; Bibby et al., 1987).
The identification of FAA led for the first time to an agent
with very broad, perhaps nearly universal solid tumour
activity (Corbett et al., 1986) and a considerable amount of
effort went into further characterising the activity in an
attempt to identify a mechanism of action. Zaharko et al.
(1986) introduced the concept of a therapeutic window below
which no activity was seen and above which lethality occur-
red. This observation was based on therapeutic experiments
in mice and toxicity studies in dogs related to projected
pharmacokinetic behaviour in these species. Subsequent
clinical studies with FAA showed that clearance and
metabolism are elevated in humans compared with mice
(Cummings et al., 1989) but nevertheless the therapeutic
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Figure I Structural formulae of a, LM985 and b, LM975.
window was easily reached in humans but no anti-tumour
activity was seen. It was suggested that critical drug concen-
trations were not being seen close to, or in human tumours
or other sites of action because of competition from
metabolism, protein binding and urinary excretion for the
active form of the drug. Recent studies from the UK
(Maughan et al., 1989) and Italy (Damia et al., 1990) have
demonstrated that tumour FAA levels in patients are similar
to those achieved in mouse studies so it is highly unlikely
that the lack of activity in human tumours is due to reduced
penetration of FAA. We are looking therefore at a difference
in mechanism of action between mouse and man.
It became clear early on in the FAA saga that the
mechanism ofaction is not direct cytotoxicity. In vitro studies
show quite clearly that extremely high concentrations or long
exposure times are necessary for direct cytotoxicity (Bibby, et
al., 1987; Schroyens et al., 1987; Capolongo et al., 1987). The
dramatic effects against mouse tumours in vivo occur at drug
exposure parameters below those necessary for in vitro cell
killing. Chabot et al. (1989) reported enhanced in vitro
cytotoxicity by FAA to human colon tumour cells in the
presence of supernatants of mouse liver homogenates (S9),
implying activation to more potent metabolites. They have
been unable to identify the products of bioactivation and
numerous in vivo pharmacokinetic studies have failed to
demonstrate active biotransformation products either in
mouse or man.
The haemorrhagic necrosis produced in mouse tumours by
FAA has been likened to the effects seen with tumour ne-
crosis factor a (TNF) where massive haemorrhagic necrosis
occurs starting as early as 2-4 h after administration (Smith
et al., 1987). Our early studies demonstrated that FAA
activity in mouse tumours was dependant upon an estab-
lished tumour vasculature (Bibby et al., 1988) and it is also
clear that tumour site is important (Finlay et al., 1988; Bibby
et al., 1989a). Significant haemorrhagic necrosis seems to be
restricted to tumours growing in a subcutaneous site. Further
studies with subcutaneous tumours have shown that these
responses are associated with a reduction in tumour blood
flow (Bibby et al., 1989b; Evelhoch et al., 1988; Zwi et al.,
1989; Hill et al., 1989) and the resultant necrosis is likely to
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be at least in part due to ischaemic injury. The underlying
mechanisms of blood flow reduction is a matter for specula-
tion but a recent elegant study by Mahadevan et al. (1990)
has confirmed the involvement of TNF. By injecting an
anti-serum against murine TNF a they virtually abolished the
FAA induced vascular shutdown in colon 26 tumours in
BALB/c mice and also abrogated totally the effects of FAA
on tumour size. This study is compatible with the work of
Mace et al. (1990), who demonstrated increased levels of
TNF a in the serum of FAA treated BALB/c mice and an
up-regulation of mRNA for TNF a in splenic leucocytes.
There can be little doubt then that the vascular shutdown
caused by FAA in murine tumours is partially or wholly
mediated by the induction of TNF a and this has a major
role to play in the anti-tumour effects. However, FAA also
has other well documented immunomodulatory effects, some
of which can also be explained on the basis of TNF induc-
tion (Semenzato, 1990). Activation of natural killer (NK) cell
activity (Ching & Baguley, 1987, 1989; Wiltrout et al., 1988;
Hornung et al., 1988) and induction of interferons (Hornung
et al., 1988; Wiltrout & Hornung, 1988) have been implicated
in the indirect mechanism of action of FAA. Urba et al.
(1988) demonstrated that the administration of FAA to
patients with advanced cancer resulted in enhancement of
NK activity in three out of six cases. Interferon (IFN) y was
not induced in any of the patients but three out of four
patients showed low levels of IFN activity which the authors
suggest was probably due to IFN a. It is likely that these
immunomodulatory effects have a role to play in the
mechanism but clearly they cannot explain the lack of
activity in -systemic tumour nodules in mice described by
ourselves (Bibby et al., 1989a) and others (Finley et al.,
1988). Enhanced NK activity may be involved in the anti-
tumour effects against human tumour xenograft deposits in
the liver of nude mice described by Pratesi et al. (1989).
In order to examine the role of immune status on the
activity of FAA in murine tumours, we looked at the anti-
tumour properties of FAA against a series of mouse colon
tumours (MAC) grown in normal NMRI, thymectomised
NMRI and nude mice (Bibby & Double, 1990). The tumours
are highly responsive to FAA in their normal NMRI hosts
but do not undergo significant responses in thymectomised
NMRI or nude hosts. Histological examination of treated
tumours revealed large areas of haemorrhagic necrosis in all
three hosts indicating that although haemorrhagic necrosis
occurs it is insufficient in itself to produce significant anti-
tumour responses. These observations bear a striking resem-
blance to those reported for endotoxin (Parr et al., 1973).
The histological appearance of subcutaneous tumours treated
with FAA is similar to that of endotoxin treated tumours
and regression brought about by endotoxin was thought to
be due to vascular damage in the tumour and activation of
macrophages present within the tumour. FAA also has been
shown to enhance the cytotoxicity of macrophages in vitro
(Ching & Baguley, 1988). Immunosuppression interferes with
the anti-tumour action of endotoxin in spite of the fact that
haemorrhagic necrosis still occurs. Subsequently it has been
suggested that TNF has a primary role in mediating
endotoxin shock (Beutler et al., 1985).
The response of subcutaneous human tumour xenografts
in nude mice to FAA appears modest (Giavazzi et al., 1988;
Finley et al., 1988; H. Fiebig, personal communication). It is
possible, however, that the lack of activity is due to the
immuno-incompetence of the host rather than an inherent
resistance of human tumours. More recent studies in this
laboratory have shown that the HT-29 human tumour
xenograft is completely resistant to FAA in nude mice and
there is no haemorrhagic necrosis or tumour blood flow
shutdown (Bibby et al., 1990). This is despite the achieve-
ment of similar plasma and tumour drug exposure para-
meters to those seen in previous studies in normal mice and
despite there being an established blood vascular supply. On
the other hand another group has seen haemorrhagic necrosis
in subcutaneous xenografts in nude mice (Finlay et al., 1988)
so the situation in human tumours is not universal.
The activity of FAA in murine tumours therefore depends
on a number of factors; firstly, achievement ofadequate drug
concentrations within the therapeutic window; secondly
establishment of an adequate blood vasculature to the
tumour; and thirdly a competent immune system. Recent
observations by Pratesi et al. (submitted) have identified a
T-cell involvement in the mechanism of action of FAA
against subcutaneous colon 26 tumours. Tumour inhibition
by FAA was reduced in BALB/c mice after in vivo depletion
of the L3T4 lymphocyte sub-population.
In view of the large body of evidence which now points to
a vascular involvement in the mechanism of action of FAA it
would seem pertinent to re-evaluate, clinically, with a view to
identifying any possible vascular effects in human cancer. It
is clear from the nude mouse studies that even in mouse
tumours, any vascular damage does not progress to
measurable tumour regression without the appropriate T-cell
component, but preliminary studies in this laboratory have
shown that responses can be achieved in MAC tumours in
nude mice by combination chemotherapy with FAA and
standard cancer agents. The relevance of these studies to
human disease needs to be established as it is clear that the
vasculature of human disease is likely to be quite different
from that of subcutaneous tumours in mice. In fact it may
relate more closely to systemic tumours in mice. The exten-
sive laboratory work with FAA then has revealed a number
of observations which are highly relevant to the development
of anti-cancer drugs in general. It is undeniable that a com-
pound which has indirect anti-tumour properties will not be
picked up in the in vitro front line screen proposed by NCI.
One might ask is this a bad thing? Do we need compounds
which are active against mouse tumours but inactive in the
clinic? Clearly we do not but until FAA has been shown to
have no influence on tumour vasculature in human cancer we
should not ignore it or compounds like it. This compound
has taught us lessons which we must assimilate and learn
from. It is clear that pre-clinical evaluation of the full poten-
tial of anti-cancer agents is highly complex as there is a need
to consider both direct and indirect effects in a drug develop-
ment programme. Evaluation of indirect mechanisms rather
than screening for cytotoxicity would be enormously expen-
sive, but if we are to develop agents with activity against
novel targets this approach is highly desirable. Experience
with FAA has taught us that we must use model systems
appropriate for the identification of compounds which have
vasculature as a target or those compounds which initiate a
host mediated response. This can only be achieved by fully
understanding the limitations of the systems we employ at
present and developing appropriate models which mimic
these targets in human cancer.
The work of the Clinical Oncology Unit at the University of Brad-
ford is funded by Bradford's War on Cancer Trust and the Turner/
Whyte Watson Cancer Research Trust.
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